A team of physicists at Fudan University, working with colleagues from Henan University, both in China, and from Nanyang ...
Our Parliamentary Affairs and Policy and Evidence teams have submitted their calls to the Government as part of the feedback process for the Spending Review.
Researchers at the Center for Life Sciences at the Paul Scherrer Institute PSI have for the first time identified structural ...
When you first enter a new world, you can either spawn near a structure or find one while exploring any of the three dimensions. While finding some can be quite easy, others are extremely hard to ...
Researchers have profiled the molecular structure and features of a key part of the deadly Nipah virus. Experiments in cells showe how changes in the viral polymerase -- a protein involved in ...
The US Food and Drug Administration (FDA) has approved sotorasib (Lumakras, Amgen Inc.) with panitumumab (Vectibix, Amgen Inc.) for the treatment of certain adult patients with metastatic ...
The international team describes their results and the underlying molecular mechanism in Cell Metabolism. Ergothioneine is a natural compound found in certain fungi such as oyster or shiitake ...
Approval is based on data from the Phase III CodeBreaK 300 trial, which demonstrated that treatment with Lumakras and Vectibix significantly improved progression-free survival in patients with KRAS ...
Three cancer drugs separately earned FDA approval: The KRAS inhibitor sotorasib (Lumakras; Amgen) was approved for use with the EGFR inhibitor panitumumab (Vectibix; Amgen) to treat patients with ...
The Food and Drug Administration has approved Amgen sotorasib (Lumakras) with panitumumab (Vectibix) for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an ...
"Colorectal cancer is the third leading cause of cancer-related deaths in the United States, and fewer than one in five people diagnosed with metastatic disease survive beyond five years after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results